Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers.
Efficacy assessment
Hepatitis B e Antigen
Hepatitis B immunoglobulin
Hepatitis B vaccine
Hepatitis B virus
Mother-to-child transmission
Journal
Journal of virus eradication
ISSN: 2055-6640
Titre abrégé: J Virus Erad
Pays: England
ID NLM: 101654142
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
28
02
2022
accepted:
16
06
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
Vertical mother-to-child transmission (MTCT) of the hepatitis B virus (HBV) remains an important issue. Timely administration of hepatitis B immunoglobulin (HBIG) and of the HBV vaccine is effective in preventing MTCT in infants born to HBV-infected mothers. However, HBIG is often not easily available in low-income countries or regions. We compared in a retrospective cohort study the HBV vaccine efficacy alone and in combination with HBIG in preventing vertical MTCT in infants born to HBeAg-negative carrier mothers in Jiangsu province, China. Based on the administration of the HBV vaccine and HBIG shortly after birth, children were divided into two groups: Group 1, administration of the HBV vaccine alone, and Group 2, concurrent use of HBIG and of the HBV vaccine. A total of 620 infants born to HBeAg-negative carrier mothers were enrolled into this study. Group 1 included 195 children who had received the HBV vaccine alone after birth, and Group 2, 425 children who had received both HBIG and the HBV vaccine. Children were followed up to the age of 68 and 42 months, respectively. MTCT of HBV occurred in 0% (0/195) in Group 1 (HBV vaccine alone) and 0% (0/425) in Group 2 (HBV vaccine and HBIG) (p = 1.00). In this retrospective cohort study, we found that HBV vaccination alone shortly after birth was effective in preventing MTCT of HBV in infants born to HBeAg-negative carrier mothers.
Sections du résumé
Background
UNASSIGNED
Vertical mother-to-child transmission (MTCT) of the hepatitis B virus (HBV) remains an important issue. Timely administration of hepatitis B immunoglobulin (HBIG) and of the HBV vaccine is effective in preventing MTCT in infants born to HBV-infected mothers. However, HBIG is often not easily available in low-income countries or regions.
Methods
UNASSIGNED
We compared in a retrospective cohort study the HBV vaccine efficacy alone and in combination with HBIG in preventing vertical MTCT in infants born to HBeAg-negative carrier mothers in Jiangsu province, China. Based on the administration of the HBV vaccine and HBIG shortly after birth, children were divided into two groups: Group 1, administration of the HBV vaccine alone, and Group 2, concurrent use of HBIG and of the HBV vaccine.
Results
UNASSIGNED
A total of 620 infants born to HBeAg-negative carrier mothers were enrolled into this study. Group 1 included 195 children who had received the HBV vaccine alone after birth, and Group 2, 425 children who had received both HBIG and the HBV vaccine. Children were followed up to the age of 68 and 42 months, respectively. MTCT of HBV occurred in 0% (0/195) in Group 1 (HBV vaccine alone) and 0% (0/425) in Group 2 (HBV vaccine and HBIG) (p = 1.00).
Conclusion
UNASSIGNED
In this retrospective cohort study, we found that HBV vaccination alone shortly after birth was effective in preventing MTCT of HBV in infants born to HBeAg-negative carrier mothers.
Identifiants
pubmed: 35813576
doi: 10.1016/j.jve.2022.100076
pii: S2055-6640(22)00014-0
pmc: PMC9260629
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100076Informations de copyright
© 2022 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Dig Liver Dis. 2020 Feb;52(2):199-204
pubmed: 31320303
MMWR Recomm Rep. 2018 Jan 12;67(1):1-31
pubmed: 29939980
Chin Med J (Engl). 2021 Oct 11;134(23):2818-2824
pubmed: 34636773
BMC Infect Dis. 2012 Sep 17;12:221
pubmed: 22984924
Gastroenterology. 2012 Apr;142(4):773-781.e2
pubmed: 22198276
Vaccine. 1995;13(8):699-702
pubmed: 7483783
Hepatology. 2016 Nov;64(5):1451-1461
pubmed: 27044007
Expert Rev Vaccines. 2021 Jul;20(7):899-905
pubmed: 33960275
J Clin Gastroenterol. 2019 Jan;53(1):51-57
pubmed: 29517711
Vaccine. 2017 Dec 4;35(48 Pt B):6627-6633
pubmed: 29079104
Hum Vaccin Immunother. 2015;11(8):2061-7
pubmed: 26090956
Singapore Med J. 2016 Oct;57(10):566-569
pubmed: 26778725
Am J Epidemiol. 1977 Feb;105(2):94-8
pubmed: 835566
Lancet Infect Dis. 2021 Jan;21(1):85-96
pubmed: 32805201
BMC Pregnancy Childbirth. 2018 Jul 6;18(1):292
pubmed: 29980185
Vaccine. 2014 Oct 21;32(46):6091-7
pubmed: 25240752
Aliment Pharmacol Ther. 2016 Nov;44(10):1005-1017
pubmed: 27630001
Clin Gastroenterol Hepatol. 2018 Jan;16(1):144-145
pubmed: 28733258
Int J Gynaecol Obstet. 2010 Jun;109(3):194-7
pubmed: 20152977
J Med Virol. 2002 Jul;67(3):327-33
pubmed: 12116022
Dig Liver Dis. 2019 Jun;51(6):864-869
pubmed: 30528568
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Lancet. 1983 Nov 12;2(8359):1099-102
pubmed: 6138642
Pediatr Infect Dis J. 2003 Jul;22(7):584-8
pubmed: 12867831
Medicine (Baltimore). 2015 Nov;94(45):e2001
pubmed: 26559291
Vaccine. 2017 Jan 3;35(1):40-45
pubmed: 27894717
Hum Vaccin Immunother. 2020 Jul 2;16(7):1533-1544
pubmed: 32186974